My guest on the show today is Larry Heaton, CEO of Zomedica (NYSE American: ZOM), a veterinary health company creating therapeutic and diagnostic products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.
Zomedica has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system.
According to a 2018 research report by Grand View Research, ”The global pet care market size was estimated at USD 131.7 billion in 2016 and is expected to grow with a CAGR of 4.9% from 2016 to 2025.” Furthermore, a 2021 ASPCA report noted that ”23 million American households acquired a pet during the COVID-19 crisis.”
I’ve seen Zomedica at many financial conferences, however, this is my first conversation with newly appointed CEO, Larry Heaton, who started this position in the company in October 2021 and I wanted to hear his thoughts since joining the company, how the company is addressing the pet care market, as well as:
Full slate of Diagnostic and Therapeutic products
How to evaluate which assays to bring on board
Regulatory differences between human and animal health markets
Capital allocation strategy
With that, please enjoy my conversation with Larry Heaton, CEO of Zomedica. For more information about Zomedica, please visit: https://zomedica.com/
This podcast was recorded and is being made available by SNN, Inc. (together with its affiliates and its and their employees, “SNN”) solely for informational purposes. SNN is not providing or undertaking to provide any financial, economic, legal, accounting, tax, or other advice in or by virtue of this podcast. The information, statements, comments, views, and opinions provided in this podcast are general in nature, and such information, statements, comments, views, and opinions, and the viewing of/listening to this podcast are not intended to be and should not be construed as the provision of investment advice by SNN. The information, statements, comments, views, and opinions expressed in this podcast do not constitute and should not be construed as an offer to buy or sell any securities or to make or consider any investment or other course of action.
The information, statements, comments, views, and opinions expressed in this podcast (including by guest speakers who are not officers, employees, or agents of SNN) are not necessarily those of SNN and may not be current. Reference to any specific third-party entity, product, service, materials, or content does not constitute an endorsement or recommendation by the SNN. SNN assumes no responsibility or liability for the accuracy or completeness of the content contained in third party materials or on third party sites referenced in this podcast or the compliance with applicable laws of such materials and/or links referenced herein. The views expressed by guest speakers are their own and their appearance on this podcast does not imply an endorsement of them or any entity they represent. SNN does not make any representation or warranty as to the accuracy or completeness of any of the information, statements, comments, views, or opinions contained in this podcast, which may include forward-looking statements where actual results may differ materially. SNN does not undertake any obligation whatsoever to provide any form of update, amendment, change, or correction to any of the information, statements, comments, views or opinions set forth in this podcast.
SNN EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIR